Tokai Pharmaceuticals Inc 4
4 · Tokai Pharmaceuticals Inc · Filed Jun 24, 2015
Insider Transaction Report
Form 4
McBride John S.
Director
Transactions
- Sale
Common Stock
2015-06-24$14.20/sh−300$4,260→ 0 total - Sale
Common Stock
2015-06-23$14.00/sh−6,700$93,800→ 0 total - Exercise/Conversion
Common Stock
2015-06-22$4.19/sh+2,000$8,380→ 2,000 total - Exercise/Conversion
Stock Option (right to buy)
2015-06-22−2,000→ 207,178 totalExercise: $4.19Exp: 2024-02-25→ Common Stock (2,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2015-06-24−300→ 200,178 totalExercise: $4.19Exp: 2024-02-25→ Common Stock (300 underlying) - Sale
Common Stock
2015-06-22$14.02/sh−2,000$28,040→ 0 total - Exercise/Conversion
Common Stock
2015-06-23$4.19/sh+6,700$28,073→ 6,700 total - Exercise/Conversion
Common Stock
2015-06-24$4.19/sh+300$1,257→ 300 total - Exercise/Conversion
Stock Option (right to buy)
2015-06-23−6,700→ 200,478 totalExercise: $4.19Exp: 2024-02-25→ Common Stock (6,700 underlying)
Footnotes (4)
- [F1]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]This option vested with respect to 12.5% of the shares underlying the option on April 1, 2014 and vests with respect to an additional 2.0833% on the first day of each month thereafter through October 1, 2017.